International Society of Glomerular Disease (ISGD)

Nephrology experts discuss how CKD care has evolved in 2026, including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and personalized treatment.

Marc Richards, MD, discusses how new therapies and combination treatment strategies are transforming evidence-based care for chronic kidney disease.

Michael Richards, MD, discusses aldosterone's role in CKD pathophysiology and why targeting this pathway may reshape kidney disease treatment.

A clinician explains how sparsentan is changing treatment strategies for patients with FSGS.

APOL1 research is driving precision nephrology, but prediction gaps and equity challenges still limit clinical impact.

An expert shares his perspective on emerging targets and precision strategies for podocyte injury in glomerular disease.

NEPTUNE and CureGN are advancing precision nephrology, linking molecular data to outcomes and enabling targeted therapies and smarter clinical trial design.

Experts discuss major advances in glomerular disease research and care, including molecular technologies, biomarker discovery, APOL1-mediated kidney disease, and evolving clinical trial design and endpoints.

Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.

The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.

PLA2R antibodies are advancing precision care in membranous nephropathy and informing new surrogate endpoints through PARASOL.

Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.

APOL1 kidney disease highlights the need for community trust, increased screening, and stronger clinical trial participation.

Rapid advances in glomerular disease, from single-cell tech to biomarkers and phase 3 trials, are reshaping diagnosis and treatment.